Circulating MicroRNAs for Early Diagnosis of Ovarian Cancer: A Systematic Review and Meta-Analysis

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2023 May 27

PMID 37238740

Authors

Nanna Lond Skov Frisk

Anja Elaine Sorensen

Ole Birger Vesterager Pedersen

Louise Torp Dalgaard

Affiliations

Soon will be listed here.

Abstract

In this study, we conducted a systematic review and meta-analysis to summarize and evaluate the global research potential of different circulating miRNAs as an early diagnostic biomarker for OC. A systematic literature search for relevant studies was conducted in June 2020 and followed up in November 2021. The search was conducted in English databases (PubMed, ScienceDirect). The primary search resulted in a total of 1887 articles, which were screened according to the prior established inclusion and exclusion criteria. We identified 44 relevant studies, of which 22 were eligible for the quantitative meta-analysis. Statistical analysis was performed using the Meta-package in Rstudio. Standardized mean differences (SMD) of relative levels between control subjects and OC patients were used to evaluate the differential expression. All studies were quality evaluated using a Newcastle-Ottawa Scale. Based on the meta-analysis, nine miRNAs were identified as dysregulated in OC patients compared to controls. Nine were upregulated in OC patients compared to controls (miR-21, -125, -141, -145, -205, -328, -200a, -200b, -200c). Furthermore, miR-26, -93, -106 and -200a were analyzed, but did not present an overall significant difference between OC patients and controls. These observations should be considered when performing future studies of circulating miRNAs in relation to OC: sufficient size of clinical cohorts, development of consensus guidelines for circulating miRNA measurements, and coverage of previously reported miRNAs.

Citing Articles

The era of increasing cancer survivorship: Trends in fertility preservation, medico-legal implications, and ethical challenges.

De Paola L, Napoletano G, Gullo G, Circosta F, Vergallo G, Marinelli S Open Med (Wars). 2025; 20(1):20251144.

PMID: 39958979 PMC: 11826245. DOI: 10.1515/med-2025-1144.

Circulating microRNAs as Diagnostic Biomarkers to Detect Specific Stages of Ovarian Cancer: A Comprehensive Meta-Analysis.

Kartikasari A, Michel-Lara P, Exton H, Tekin-Sari K, Alnefai E, Mitchell A Cancers (Basel). 2025; 16(24.

PMID: 39766088 PMC: 11674734. DOI: 10.3390/cancers16244190.

Deciphering the roles of non-coding RNAs in liposarcoma development: Challenges and opportunities for translational therapeutic advances.

Chong Z, Ho W, Yeap S Noncoding RNA Res. 2024; 11:73-90.

PMID: 39736850 PMC: 11683247. DOI: 10.1016/j.ncrna.2024.11.005.

Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies.

Lazaridis A, Katifelis H, Kalampokas E, Lambropoulou D, Aravantinos G, Gazouli M Int J Mol Sci. 2024; 25(21).

PMID: 39519256 PMC: 11546551. DOI: 10.3390/ijms252111703.

Altered exosomal miRNA profiles in patients with paraneoplastic cerebellar degeneration.

Tveit Solheim E, Vestrheim Thomsen L, Bjorge L, Anandan S, Peter E, Desestret V Ann Clin Transl Neurol. 2024; 11(12):3255-3266.

PMID: 39473143 PMC: 11651201. DOI: 10.1002/acn3.52232.

References

Marton E, Lukacs J, Penyige A, Janka E, Hegedus L, Soltesz B . Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer. J Biotechnol. 2019; 297:58-65. DOI: 10.1016/j.jbiotec.2019.04.003. View

Meng X, Muller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H . Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer. Adv Exp Med Biol. 2016; 924:3-8. DOI: 10.1007/978-3-319-42044-8_1. View

Xie K, Zhang K, Kong J, Wang C, Gu Y, Liang C . Cancer-testis gene PIWIL1 promotes cell proliferation, migration, and invasion in lung adenocarcinoma. Cancer Med. 2017; 7(1):157-166. PMC: 5774002. DOI: 10.1002/cam4.1248. View

Chen Z, Guo X, Sun S, Lu C, Wang L . Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses. Bioengineered. 2020; 11(1):311-317. PMC: 7161537. DOI: 10.1080/21655979.2020.1736755. View

Buys S, Partridge E, Black A, Johnson C, Lamerato L, Isaacs C . Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305(22):2295-303. DOI: 10.1001/jama.2011.766. View

Ren X, Zhang H, Cong H, Wang X, Ni H, Shen X . Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer. Pathol Oncol Res. 2018; 24(4):739-744. DOI: 10.1007/s12253-018-0392-x. View

Choi P, Bahrampour A, Ng S, Liu S, Qiu W, Xie F . Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer. Sci Rep. 2020; 10(1):20071. PMC: 7674435. DOI: 10.1038/s41598-020-77068-0. View

Langhe R, Norris L, Saadeh F, Blackshields G, Varley R, Harrison A . A novel serum microRNA panel to discriminate benign from malignant ovarian disease. Cancer Lett. 2014; 356(2 Pt B):628-36. DOI: 10.1016/j.canlet.2014.10.010. View

Kerber R, Slattery M . The impact of family history on ovarian cancer risk. The Utah Population Database. Arch Intern Med. 1995; 155(9):905-12. View

10.

Kozomara A, Birgaoanu M, Griffiths-Jones S . miRBase: from microRNA sequences to function. Nucleic Acids Res. 2018; 47(D1):D155-D162. PMC: 6323917. DOI: 10.1093/nar/gky1141. View

11.

Oliveira D, Carlsen A, Heegaard N, Prahm K, Christensen I, Hogdall C . Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass. PLoS One. 2019; 14(11):e0225249. PMC: 6860451. DOI: 10.1371/journal.pone.0225249. View

12.

Pirlog R, Chiroi P, Rusu I, Jurj A, Budisan L, Pop-Bica C . Cellular and Molecular Profiling of Tumor Microenvironment and Early-Stage Lung Cancer. Int J Mol Sci. 2022; 23(10). PMC: 9140615. DOI: 10.3390/ijms23105346. View

13.

Liu Y, Zong Z, Guan X, Wang L, Zhao Y . The role of long non-coding RNA PCA3 in epithelial ovarian carcinoma tumorigenesis and progression. Gene. 2017; 633:42-47. DOI: 10.1016/j.gene.2017.08.027. View

14.

Hirsch M, Duffy J, Davis C, Nieves Plana M, Khan K . Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis. BJOG. 2016; 123(11):1761-8. DOI: 10.1111/1471-0528.14055. View

15.

Faramin Lashkarian M, Hashemipour N, Niaraki N, Soghala S, Moradi A, Sarhangi S . MicroRNA-122 in human cancers: from mechanistic to clinical perspectives. Cancer Cell Int. 2023; 23(1):29. PMC: 9940444. DOI: 10.1186/s12935-023-02868-z. View

16.

Schwarzenbach H, Nishida N, Calin G, Pantel K . Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11(3):145-56. DOI: 10.1038/nrclinonc.2014.5. View

17.

Moore R, Miller M, Steinhoff M, Skates S, Lu K, Lambert-Messerlian G . Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012; 206(4):351.e1-8. PMC: 3985608. DOI: 10.1016/j.ajog.2011.12.029. View

18.

Kan C, Hahn M, Gard G, Maidens J, Huh J, Marsh D . Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer. 2013; 12:627. PMC: 3542279. DOI: 10.1186/1471-2407-12-627. View

19.

Lin L, Gan H, Zhang H, Tang W, Sun Y, Tang X . MicroRNA‑21 inhibits SMAD7 expression through a target sequence in the 3' untranslated region and inhibits proliferation of renal tubular epithelial cells. Mol Med Rep. 2014; 10(2):707-12. DOI: 10.3892/mmr.2014.2312. View

20.

Wang W, Yin Y, Shan X, Zhou X, Liu P, Cao Q . The Value of Plasma-Based MicroRNAs as Diagnostic Biomarkers for Ovarian Cancer. Am J Med Sci. 2019; 358(4):256-267. DOI: 10.1016/j.amjms.2019.07.005. View